story of the week
Elacestrant vs Standard Endocrine Therapy for ER+/HER2− Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
J. Clin. Oncol 2022 May 18;[EPub Ahead of Print], FC Bidard, VG Kaklamani, P Neven, G Streich, AJ Montero, F Forget, MA Mouret-Reynier, JH Sohn, D Taylor, KK Harnden, H Khong, J Kocsis, F Dalenc, PM Dillon, S Babu, S Waters, I Deleu, JA García Sáenz, E Bria, M Cazzaniga, J Lu, P Aftimos, J Cortés, S Liu, G Tonini, D Laurent, N Habboubi, MG Conlan, A BardiaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.